Your SlideShare is downloading. ×
2013 06 22_biosten_spief_with_video
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

2013 06 22_biosten_spief_with_video

3,915

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
3,915
On Slideshare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Biosten LLC:Developing bioresorbable endovascular stents
  • 2. Cardiovascular diseases take more lives inRussia than other mortality causes combined020040060080010001200Infections RespiratorydiseasesDigestive diseases External causes Cancer Cardio- vasculardiseasesMortalityin2011г.,thousandsMortality causes in Russia
  • 3. Coronary stents decrease mortality fromcoronary artery disease andacute coronary syndrome• Coronary stent opens the narrowed vessel and restoresnormal blood flow• Coronary stenting reduce hospital mortality in patients withacute coronary syndrome by 75%
  • 4. In coronary stenting, Russia lags behind0102030405060USA EU27 RussiaCoronary stentsannual use per 10000• More than 1.5 millioncoronary stents used inUSA annually.• About 1 million coronarystents used in EU.• Only 77 thousand coronarystents used in Russia.
  • 5. But…coronary stents could be betterBare-metal stents and drug-elutingstents with metal frames savelives, but have their owndisadvantages• Restenosis• Several years of anti-clottingmedication• Metal burden in the body
  • 6. The 4th revolution in angioplasty:bioresorbable stents• Leave a naturally healed vesselwithout permanent metallicimplant, allowing normal vasomotionand late expansive remodeling.• Minimize chronic inflammatoryeffects of coating and metallicplatform, potentially shortening theduration of dual anti-platelet therapy• Facilitate re-intervention (PCI andCABG)– late reexpansion possible , nojailed sidebranches and no ‘’fullmetal jacket’’.
  • 7. Biosten LLC: developing bioresorbable stentsof the next generation• Identifying polymercomposition with desiredresorption rate (in-vivo)• Making polymer tubeswith certain mechanicalproperties• Laser cutting stents frompolymer tubes
  • 8. Biosten results:• We developed and demonstrated biodegradable stent prototypesas a proof of project concept.• Technology is patented and patent pending.
  • 9. Stent prototype deployment in vessel model
  • 10. Biosten results:• Evaluatedbiocompatibility, cytotoxicity, andbiodegradation• Formed a project team that focuses oncommercialization and sustainabilityof the R&D projectContacts:Dr. Oksana Manzenyuk, Project manager,Biosten LLC , o.manzenyuk@stentex.ru

×